Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

TriSalus Life Sciences (TLSI) EBITDA Margin (2022 - 2025)

Historic EBITDA Margin for TriSalus Life Sciences (TLSI) over the last 4 years, with Q3 2025 value amounting to 77.94%.

  • TriSalus Life Sciences' EBITDA Margin rose 409800.0% to 77.94% in Q3 2025 from the same period last year, while for Sep 2025 it was 77.74%, marking a year-over-year increase of 815500.0%. This contributed to the annual value of 122.88% for FY2024, which is 1714000.0% up from last year.
  • As of Q3 2025, TriSalus Life Sciences' EBITDA Margin stood at 77.94%, which was up 409800.0% from 65.39% recorded in Q2 2025.
  • TriSalus Life Sciences' 5-year EBITDA Margin high stood at 65.39% for Q2 2025, and its period low was 364.91% during Q4 2022.
  • Its 4-year average for EBITDA Margin is 191.69%, with a median of 180.77% in 2024.
  • In the last 5 years, TriSalus Life Sciences' EBITDA Margin tumbled by -1517300bps in 2023 and then skyrocketed by 2395700bps in 2024.
  • TriSalus Life Sciences' EBITDA Margin (Quarter) stood at 364.91% in 2022, then surged by 32bps to 249.05% in 2023, then soared by 63bps to 91.76% in 2024, then rose by 15bps to 77.94% in 2025.
  • Its EBITDA Margin was 77.94% in Q3 2025, compared to 65.39% in Q2 2025 and 79.95% in Q1 2025.